POSTER ABSTRACT
SESSION #1
Sunday, August 17th, 2003 - Staffed
from 7:45 a.m. - 8:45 a.m.
|
| Number |
Genetics (6)
|
Presenting Author |
| 008 |
European Molecular Genetics Quality
Network: External Quality Assessment for the Molecular Diagnosis
of Huntington Disease in Europe (1997-2002) |
Monique Losekoot, PhD |
| 009 |
Monozygotic Twins Displaying Mosaicism of an Expanded and
an Intermediate Allele of the CAG Repeat in the Huntington
Disease Gene
|
Anne Norremolle, PhD |
| 020 |
Study of Juvenile Huntington Disease
Patients of Italian Origin |
Ferdinando Squitieri, MD, PhD |
| 036 |
Molecular Analysis of Turkish Huntington's Disease Patients
|
Nazli Basak, PhD |
| 057 |
Sequence and Haplotype Analysis of
GRIK2 (GluR6) in Huntington Disease: Assessment of a Modifier
Gene |
Wen-Qi Zeng, MD, PhD |
| 071 |
Molecular Study of Huntington Disease
in Iranian Families |
Fabiola Hormozian, Ms.c in Genetics |
| |
Genetic Counseling (7)
|
|
| 010 |
UK Study of Reduced Penetrance Alleles in Huntington's
Disease |
Oliver Quarrell, MD, FRCP |
| 012 |
Reproductive Decision Making Before and After
Predictive Testing for Huntington Disease: An Australian Perspective |
Fiona Richards, Master of Social Work |
| 019 |
Predictive Testing in Huntington Disease Families With Patients
Homozygous for CAG Mutation
|
Ferdinando Squitieri, MD, PhD |
| 021 |
Non-Consensual Predictive Testing:
Testing at 25% risk-Some Legal and Counseling Issues Encountered
in Australia |
Roslyn Tassicker, Master of Social
Work |
| 044 |
Preimplantation Diagnosis for Huntington
Disease-The London Experience |
Alison Lashwood, MSc. Genetic Counseling |
| 046 |
The Impact of Presymptomatic Predictive
Testing for Huntington's Disease on Partners and Marital Relationships:
Secrets, Lies and Truths |
Anita Bruce, BSc |
| 060 |
Personality Traits in Probands Undergoing Predictive
Testing for Huntington Disease |
Elisabeth Almqvist, PhD, RN |
| |
Psychosocial Issues (8)
|
|
| 005 |
Adverse Effects of Predictive Testing for Huntington
Disease Underestimated: Long Term Effects 7-10 Years After the
Test |
Reinier Timman, MA |
| 006 |
Informing Relatives About Genetic Risk: A Qualitative
Study of Patients At Risk For Huntington's Disease or Hereditary
Breast/Ovarian Cancer |
Karen Forrest, MLitt |
| 014 |
Innovative Approaches to Improving the Acceptance
of Texture |
Karen Keast, BSc |
| 023 |
Effects of Rehabilitation on Motor Performance,
Mood State and Everyday Life of HD Patients |
Paola Zinzi, psychology |
| 047 |
Improving Psychiatric Outcomes in an Outpatient
HD Population |
Teresa Tempkin, RNC, MSN, ANP |
| 062 |
Parenting Patterns in Patients with Huntington's
Disease |
Ellizabeth McCusker, MBBS, FRACP |
| 066 |
Who Killed That Lady? A HD Murder Case in Japan |
Kaori Muto, PhD |
| 092 |
Self-Understanding and Identity: The Experience
of Adolescents At Risk for Huntington's Disease |
Jessica Easton, M.A. |
| |
Pathogenetic Mechanisms (3)
|
|
| 004 |
Homozygosity For CAG Mutation in Huntington Disease is Associated
With a More Severe Clinical Course
|
Ferdinando Squitieri, MD, PhD |
| 017 |
Genetic Disruption
of Tissue Transglutaminase Delays Disease Progression in a Mouse
Model of Huntington's Disease |
Craig Bailey, PhD |
| 051 |
Analysis of Huntingtin Protein-Protein
Interactions Using the Yeast Two-Hybrid System |
Heike Goehler |
| |
Cell Dysfunction (5)
|
|
| 015 |
Specific Progressive cAMP Reduction
Implicates Energy Deficits in Presymptomatic HD Knock-in Mice |
Silvia Gines-Padros, PhD Biochemistry |
| 039 |
Abnormal Morphology of HD Fibroblasts Grown in
Enriched Culture Medium |
Lis Hasholt, Dr. Med.Sci. |
| 058 |
A Quantitative Gene Expression Analysis Of Laser-Dissected
Striatal Neurons In The R6/2 Mouse Model Of Huntington's Disease |
Birgit Zucker, MD |
| 074 |
Heat Shock Protein 27 Protects Monkey Cos Cells
Against Oxidative Stress Generated by the Expression of Mutant
Huntington Exon 1 |
Wance J.J. Firdaus, DEA, MSc |
| 075 |
Huntington Expression Results in a Decrease of
Proteasome Activity and Triggers Apoptosis in PC12 Cells |
George Lawless |
| |
Other (11)
|
|
| 002 |
Huntington Disease in Cuba |
Tatiana Zaldivar Vaillant, MD |
| 007 |
The Effect of Huntington's Disease on the Ability
to Respond to Conflicting Spatial Stimuli |
Nellie Georgiou-Karistianis, PhD |
| 011 |
Small Compounds That Inhibit Mutant Huntingtin
Aggregation: Potential Therapeutics of HD Patients |
Wang Jin, PhD |
| 013 |
An Abnormal Sleep Pattern and Excessive Movements
Can Characterize Patients With Huntington's Disease |
Marieta Anca, MD |
| 025 |
Comparisons of CAG Repeat Distributions for Familial
and Sporadic HD Cases & Intermediate Allele Frequencies
For Different Populations Support a Stepwise Model for CAG Expansion |
Lilias Barron, BSc |
| 027 |
Multidisciplinary Care in the Information Age
a System for Coordination of Care Amongst Geographically Dispersed
Providers |
Ronald Risley, MD |
| 029 |
The Huntingtin-Interacting Protein Endophilin
A3 Forms Filamentous Structures Which Associate With Microtubules
But Not With Actin Filaments |
Alis Hughes, Ms |
| 040 |
High Throughput Screen To Identify Compounds That
Downregulate Intracellular Mutant Huntingtin Expression |
Deborah Russel, BA |
| 045 |
PEG Feeding In End Stage Huntington's Disease:
An Examination of the Clinical and Ethical Issues, Including
the Views of the Doctor, Patient and the Patient's Family |
Sheila Simpson, MBChB, BSc, MD |
| 052 |
Motor Deficits and Striosome Volume in the YAC72
Mouse Model of Huntington's Disease |
Collene Lawhorn, BS, MS Ed |
| 076 |
Bilateral GP Stimulation for Huntington's Disease |
Elena Moro, MD, PhD |
POSTER ABSTRACT
SESSION #2
Monday, August 18th, 2003 - Staffed
from 8:00 a.m. - 9:00 a.m.
|
| |
Neuronal Vulnerability
and Survival (1)
|
|
| 061 |
mRNA Profiling of Two Striatal Neuron Populations
with Differential Vulnerability in HD: A Study Utilizing LCM,
Real-Time PCR, and cDNA Microarrays |
Sarah Augood, PhD |
| |
Cellular-Based and Genetic Animal Models
(5)
|
|
| 037 |
Interaction Between Huntingtin and the Nuclear
Receptor Corepressor |
Nagehan Ersoy, MSc |
| 042 |
Identification in Cell Culture of Small, Recruitment
Positive Polyglutamine Aggregates: Aggregation Foci |
Erica Johnson, BS |
| 054 |
Toxicity of a Carboxyl-Terminal Huntingtin Fragment
in Drosophila |
Hui Zhu, PhD |
| 064 |
Suppression of a Polyglutamine Toxicity by a Drosophila
Ortholog of MRJ |
Parsa Kazemi-Esfarjani, B.Sc., PhD |
| 077 |
The Role of Calpain in Huntington's Disease |
Lisa Ellerby, PhD |
| |
Animal Model Experimental Therapeutics
(5)
|
|
| 003 |
A Strategy for Drug Discovery in Huntington's
Disease |
Laure Jamot, PhD |
| 026 |
A Dual Role of Adenosine A2A Receptors in 3-Nitropropionic
Acid-Induced Striatal Lesions: Implications for the Neuroprotective
Potential of A2A Antagonists |
David Blum, PhD |
| 038 |
PEI Mediated In Vivo Gene Transfer in Transgenic
Huntington's Disease Mice. Evaluation of Transfection Method,
Effect and Biomarkers |
Bjarke Naver, MSc |
| 043 |
Histone Deacetylase Inhibitors Prevent Oxidative
Neuronal Death Independent of Expanded Polyglutamine Repeats
via a Sp1-Dependent Pathway |
Hoon Ryu, PhD |
| 053 |
Use of Adult Bone Marrow Stem Cell Transplants
to Counteract Cognitive Deficits in a Rat Model of Huntington's
Disease |
Gary Dunbar, PhD |
| |
Clinical Characteristics (20)
|
|
| 016 |
Subcortical Mild Cognitive Impairment: A Novel
Concept of Mental Dysfunction |
Raphael Bonelli, MD |
| 018 |
Nature and Development of HD in a Nursing Home
Population: The Further Development of the BOSH Rating Scale |
Hans Claus, MSC |
| 024 |
Objective Assessment of Akinesia and Bradykinesia
in Huntington's Disease |
Jeroen van Vugt, MD, PhD |
| 028 |
Somatoform Disorders as the Initial Presentation
of Huntington Disease |
Vicki Wheelock, MD |
| 031 |
Does the Clinical Spectrum of Huntington's Disease
Include Tremor |
Neil Mahant, MBBS |
| 033 |
Stereotypic Leg Movements in a Family Member of
Huntington's Disease |
Din-E Shan, MD, PhD |
| 034 |
Psychomotor Slowing and Memory Disturbances Over
a Three-Year Period in Presymptomatic' carriers for Huntington's
Disease |
Marie-Noelle Witjes-Ane, MSc |
| 035 |
Assessment of Change in Cognitive Function in
Huntington's Disease |
Julie Snowden, PhD |
| 041 |
Does the Cause of Functional Disability Change
With Disease Progression in Patients with Huntington's Disease? |
Yvette Grimbergen, MD |
| 048 |
Changes in Sexual Behaviour Associated with Huntington's
Disease |
David Craufurd, FRCPsych |
| 050 |
Walk and Drink Time; Objective Measures of Motor
Progression in Huntington's Disease |
Elizabeth Howard, BSc, MB ChB, MRCGP |
| 055 |
Social Cognition in Huntington's Disease and Frontotemporal
Dementia |
Jennifer Thompson, B.Sc |
| 069 |
Defining Progression in Huntington Disease |
Donald Higgins, MD |
| 070 |
Safety and Feasibility of the Prospective Huntington
At Risk Observational Study (PHAROS): A Progress Report |
Elise Kayson, MS, RNC |
| 072 |
Clinical Predictors of Neuropathological Severity:
A Prospective Autopsy Study of 100 Individuals with Huntington's
Disease |
Adam Rosenblatt, MD |
| 073 |
Risk factors for Osteoporosis in Women with Huntington's
Disease in a Long-term Care Setting |
Ayana Duckett, BA |
| 079 |
Peg Insertion Reflects Dysfunction in Huntington's
Disease |
Carsten Saft, MD |
| 082 |
Implicit Processes in People with Huntington's
Disease |
Kristy Bolter, PhD |
| 085 |
Episodic Memory Impairment in Huntington's Disease:
a Meta-Analysis |
Alonso Montoya, MD |
| 091 |
Pupillary Measure of Brainstem Activation is Reduced
in Huntington's Disease |
Francois Richer, PhD |
| |
Neuroimaging (5)
|
|
| 030 |
Progression of Structural Neuropathology in Huntington's
Disease Using Voxel and Tensor Based Morphometry |
Christopher Kipps, MBBS |
| 056 |
Quantification of Caudate and Putamen Atrophy
by Volumetric MRI in Patients with Huntington Disease. Association
Between Length of the CAG Repeat and Age at Onset |
Heloisa Ruocco, PhD |
| 059 |
Brain Energy Metabolism in Huntington's Disease |
Marguerite Wieler, BScPT |
| 065 |
MRI and PET Assessment of Brain Involvement in
Subjects With Presymptomatic, Initial and Advanced Huntington
Disease |
Ferdinando Squitieri, MD, PhD |
| 090 |
Frontal Hypoactivation and Reduced Voluntary Control
in Early Huntington's Disease |
Francois Richer, PhD |
| |
Human Experimental Therapeutics (8)
|
|
| 001 |
Targeted Nucleotide Exchange in the CAG Repeat
Region of the Human HD Gene |
Eric Kmiec, PhD |
| 022 |
Increased Cell Proliferation and Neurogenesis
in Huntington's Disease |
Maurice Curtis, BhSc, MSc |
| 032 |
Treatment of Huntington's Disease Using Essential
Fatty Acids (Long Term Follow Up Case Presentation) |
Krisna Vaddadi, FRC Psych |
| 049 |
Measurement of Irritability in Huntington's Disease |
David Craufurd, FRC Psych |
| 063 |
Ethyl-Eicosapentaenoate (Ethyl-Epa) in Huntington's
Disease: A Randomised, Placebo-Controlled Trial |
Blair Leavitt, MD, CM |
| 067 |
Management of Huntington's Disease: An Evidence-Based
Review |
Raphael Bonelli, MD |
| 088 |
Mechanism of Action of the Anti-Chorea Drug tetrabenazine:
A Review |
Kathleen Clarence-Smith, MD, PhD |
LATE-BREAKING
RESEARCH (8 POSTERS)
|
| |
Pathogenetic Mechanisms (1)
Poster will be staffed on Sunday,
August 17th, 2003
7:45 a.m. - 8:45 a.m.
|
|
| 087-LBR- |
Msh2 Protein in Base-excision Mediated CAD Expansion |
Irina Kovtun |
| |
Cellular-Based and Genetic Animal Models
(2)
Poster will be staffed on Monday,
August 18th, 2003
8:00 a.m. - 9:00 a.m.
|
|
| 078-LBR |
Behavioral Manifestations of High Extracellular
Dopamine in HdhQ92 Knock-in Mice |
Michel Cyr, PhD |
| 083-LBR |
Cell Culture Screen Identifies Caspase Inhibitors
as Potential Drugs for the Treatment of Huntington's Disease |
Charity Aiken |
| |
Animal Model Experimental Therapeutics
(1)
Poster will be staffed on Monday,
August 18th, 2003
8:00 a.m. - 9:00 a.m.
|
|
| 086-LBR |
Cop-1 Vaccination Reduces Motor Function Deficits
and Increases Life Expectancy in a Transgenic Mouse Model of
Huntington's Disease |
Yona Gefen, PhD |
| |
Clinical Characteristics (3)
Poster will be staffed on Monday,
August 18th, 2003
8:00 a.m. - 9:00 a.m.
|
|
| 080-LBR |
Is 41 Better Than 45? Influence of Low CAG Ranges
on Huntington's Disease |
Carsten Saft, MD |
| 081-LBR |
Emerging Cohort Characteristics in the Prospective
Huntington At Risk Observational Study (PHAROS) |
Kevin Biglan, MD |
| 089-LBR |
Initial Baseline Characteristics in the PREDICT-HD
(Neurobiological Predictors of HD) Study |
Jane Paulsen, PhD |
| |
Neuroimaging (1)
Poster will be staffed on Monday,
August 18th, 2003
8:00 a.m. - 9:00 a.m.
|
|
| 084-LBR |
Onset and Rate of Change in Basal Ganglia Volume
in Presymptomatic Subjects |
Elizabeth Aylward, PhD |
